CB 399: Ras Signaling in Cancer Fall 2013

Ras Signaling in Cancer
Nanocourse Faculty: Karen Cichowski, Kevin Haigis, William Hahn
Curriculum Fellow: Meg Mittelstadt, meganmittelstadt@gmail.com

At least 15% of all human cancers possess mutations in Ras oncogenes; however, mutations in upstream regulators and downstream effectors are also prevalent. In total, the Ras pathway is deregulated in the majority of human cancers.  Nevertheless, while Ras has been extensively studied for 30 years, it is still unknown how this pathway drives human cancer. In this nanocourse, we will compare and contrast Ras signaling and its regulation in both normal and cancer cells with an emphasis on recent novel discoveries. Current and future therapeutics that target Ras or Ras-dependent pathways will also be discussed.

Schedule:

First Session: Wednesday November 13, 2013, 1:00 PM – 4:00 PM
Location: Goldenson Building, Room 122
 
Second Session: Thursday, November 21, 2013 10:00 AM - 12:30 PM
Location: TMEC Building, Room 448

 

 DROP DEADLINE: Wednesday, November 6, 2013

 

AUDITORS (Post-Docs, Faculty, or Staff) DO NOT NEED TO SIGN UP TO ATTEND THE 1st SESSION.  PLEASE DO NOT ENROLL